stockrow
Saturday 7 November 2026
Export AIDX’s income statement to Excel — free account
20/20 Biolabs Inc.
AIDX Healthcare Medical Devices
20/20 Biolabs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 16.7% from fiscal 2024.
0.20
0.01
+5.26%
Follow AIDX
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+2 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
0.00 | — | 0.00 | 2.73 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(59.91) | — | (11.17) | (9.80) | |
P/B ratio |
0.00 | — | 5.64 | 3.66 | |
Price to Tangible BV |
0.00 | — | 9.48 | 9.42 | |
EV/Sales |
0.00 | — | 0.00 | 1.07 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(20.70) | — | (2.62) | (0.53) | |
EV/FCF |
(20.70) | — | (2.62) | (0.53) | |
Quick Ratio |
— | 0.50 | 1.71 | 1.90 | |
Current Ratio |
— | 0.60 | 1.82 | 1.99 | |
Net Debt/EBITDA |
0.00 | 0.00 | 3.29 | 4.77 | |
Debt/Assets |
0.00% | 16.77% | 5.28% | 0.00% | |
Debt/Equity |
0.00 | (36.15) | 0.11 | 0.00 | |
Asset Turnover |
— | — | 0.00 | 0.71 | |
Operating CF/Net income |
0.64 | 0.00 | 0.61 | 0.22 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
(939.67) | — | (5.41) | (4.57) | |
Research and Development Expense of Revenue |
36.27% | — | 43.44% | 35.26% | |
Selling, General and Administrative Expense of Revenue |
152.27% | — | 382.80% | 176.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.26 | 0.18 | 0.16 | |
Share Based Compensation of Revenue |
24.22% | — | 36.33% | 50.82% | |
Graham Net Nets |
(0.02) | — | 0.11 | 0.36 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(158.71%) | — | (158.71%) | (158.71%) | |
Free Cash Flow Yield |
(4.82%) | — | (29.39%) | (73.27%) | |
Revenue per Share |
0.11 | — | 0.05 | 0.07 | |
Operating CF per Share |
(0.11) | 0.00 | (0.17) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | 0.00 | (0.17) | (0.06) | |
Cash per Share |
0.00 | 0.00 | 0.55 | 0.42 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.36 | 0.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.36 | 0.29 | |
Free Cash Flow |
(0.53) | (1.92) | (1.29) | (0.61) | |
Working Capital |
— | (0.99) | 2.12 | 2.52 | |
Capital Expenditures |
— | 0.00 | (0.01) | 0.00 | |
Net Current Asset Value |
0.00 | (2.69) | 1.65 | 2.11 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
— | — | 4.69 | 3.06 |
Columns are period end dates